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Early Steps
Identification of tyrosine kinases with a critical role 
in cancer. As cloning technologies improved over the past 
few decades, cloning of large gene transcripts became avail-
able and allowed for the identification of cDNA, encoding for 
biologically relevant physiological peptide kinases and growth 
factors, including the group of tyrosine kinases (TKs). TKs 
are involved in multiple aspects of a “normal cell life.” They 
take part in essential processes, including cell signaling, dif-
ferentiation, proliferation, and survival. Most receptor TKs 
are transmembrane proteins that bind extracellular ligands 
and hand over the signal to cytoplasmic effector and adaptor 
proteins to regulate biological processes. Nonreceptor TKs, 
typically, are located in the cytoplasm and include many well-
characterized proteins, such as the Src family kinases, c-Abl, 
and Jak kinases.
Their potential participation in cancer development and 
cancer cell function was suggested when a close relationship 
of epidermal growth factor receptor (EGFR) and the viral 
oncogene v-erbB1,2 was revealed, and cloning of chromosomal 
translocations associated with malignancies enabled the char-
acterization of oncogenic gene alterations.
Enhanced TK activity or constitutively active kinase activ-
ity with quantitatively and qualitatively altered downstream 
signaling has been regularly found in human malignancies.
These dysregulations are caused by gene amplification or 
overexpression of protein tyrosine kinases (PTKs) as in the 
case of HER2 and breast cancer and genomic rearrangements 
or chromosomal translocations resulting in fusion proteins 
as in the case of BCR-ABL and chronic myeloid leukemia 
(CML). Another example in this direction is the anaplastic 
lymphoma kinase in anaplastic large cell lymphoma.3 Further-
more, gain of function mutations or deletions in PTKs within 
the kinase domain or extracellular domain play a role as in 
the case of EGFR mutations and certain types of lung cancer. 
Mutations causing aberrant B-cell receptor activation are also 
relevant as in the case of Bruton’s tyrosine kinase (BTK) and 
B-cell lymphomas.4
Past Era
Development of specific TK inhibitors for known TK 
targets. The first targeted antikinase therapeutic agent was 
the monoclonal antibody trastuzumab used in the treatment 
of breast cancer. The discovery of HER2 gene amplification in 
breast and ovarian cancers was the basic finding that triggered 
the development of this antibody.
With advanced technologies, analysis of TK transform-
ing properties became possible, and structure–function stud-
ies facilitated the development of small molecule inhibitors, 
specifically targeting constitutively activated protein kinases.
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Specific TK inhibitors were developed to interfere with 
TK enzymes that are aberrantly activated in tumor cells and 
are critical to tumor growth. Antibodies against TK receptors 
or their ligands interrupt TK signaling through interference 
of the ligand-receptor binding. Many other TK inhibitors are 
designed to directly block the catalytic activity of the kinase 
by interfering with the binding of ATP or substrates. In 2001, 
imatinib was the first selective TK inhibitor that was approved 
by the FDA for use in patients with CML.5,6 This small mole-
cule revolutionized the treatment and prognosis of Philadelphia 
chromosome-positive CML.7 Since imatinib potently inhib-
ited the TKs such as Platelet-derived growth factor recep-
tor (PDGFR) and KIT, the FDA approved its use also for 
patients with advanced GIST. Up to now, numerous anti-TK 
small molecules or monoclonal antibodies were integrated into 
therapeutic guidelines in different cancer entities, solid tumors 
(eg, bevacizumab, sunitinib, and gefitinib), and hematological 
malignancies (eg, ruxolitinib,8 ibrutinib, and idelalisib9).
TK inhibitors, typically, are orally administered and gen-
erally exhibit good tolerability that distinguishes these agents 
from conventional cytotoxic chemotherapies. However, as also 
seen with other drugs, efficacy of TK inhibitors is limited by 
the development of resistance. Mechanisms leading to drug 
resistance of tumor cells are manifold, often described are 
mutations, mostly point mutations that impede TK inhibitor 
binding,10,11 altered gene copy numbers, and protein expression 
level, which lead to restoration of oncogenic signaling in the pres-
ence of a given drug concentration (eg, bcr-abl amplification)12 
or increased drug efflux via increased MDR-1 expression.13 
In order to overcome mutational escape routes, TK inhibitor 
designs were optimized and second/third-generation TK inhib-
itors became available.14 Since second-generation TK inhibitors 
induced better responses compared to imatinib in patients with 
newly diagnosed chronic-phase CML, nilotinib and dasatinib 
were also approved for first-line treatment. However, there is 
less clinical experience and long-term effects need to be com-
pared to imatinib. Ponatinib, as a third-generation TK inhibitor, 
was the effective TK inhibitor in patients with T315I so far.
Present and Future Steps
Application of available TK inhibitors across differ-
ent tumor stages and cancer entities. Some TKs like BCR-
ABL are restricted to specific types of cancer, but others are 
commonly expressed and exhibit tumor-promoting activity in 
many solid tumors, such as EGFR. Targeting EGFR, there-
fore, affects various tumor cell types. However, efficiency is 
not as striking compared to BCR-ABL, because EGFR is not 
the only molecule driving the tumor growth.
As TKs are essential in many physiological functions 
and are involved, if dysregulated, in many general tumori-
genic processes like invasion, metastasis, and prolonged sur-
vival, targeting TK activity is successful across disease stages 
and also across different cancer entities (eg, anti-EGFR in 
NSCLC, colon cancer, etc, as well as anti-BTK in diffuse large 
cell lymphoma, mantle cell lymphoma, etc). Therefore, current 
studies address the search for new TK targets to broaden TK 
inhibitor application by analyzing tyrosine kinomes in differ-
ent cancers using high-throughput sequencing technologies or 
microarray-based technologies combined with bioinformatics.
Another option could be “drug repositioning” on the search 
for the ideal TK inhibitor out of the already existing pool of TK 
inhibitors. An unbiased drug sensitivity and resistance testing 
of patient-derived cancer cells could reveal new drug–target 
interactions and, thereby, provide a basis for different and/or 
broader clinical applicability of TK inhibitors. One example 
is axitinib, an antiangiogenic drug already approved for renal 
cancer, that has recently been shown to potently inhibit the 
highly resistant T315I mutation of the bcr-abl gene.15
Beside the “effectiveness” criterion, safety/clinical appli-
cability is also of great importance. Different TK inhibitors 
exhibit unique toxicity profiles and – given a comparable 
efficiency – selection of the ideal TK inhibitor can be adapted 
to individual patients with certain comorbidities, for example, 
in the case of a CML with T315I mutation: ponatinib with 
side effects like hypertension, rash, and abdominal pain versus 
axitinib with side effects like cardiac insufficiency, embolic/
thrombotic events, and bleedings.
Perspective
TK inhibitors proved to be very efficient and established a 
new treatment option in various cancer entities. However, to 
which extent TK inhibitors can facilitate disease eradication is 
still unclear. Results from both the STOP-Imatinib study and 
the TWISTER study showed that molecular remissions sus-
tained in 40%–50% of the patients for at least 12–24 months 
after imatinib cessation.16,17 To estimate the long-term effi-
cacy of TK inhibitor cessation, more discontinuation studies 
and especially longer follow-ups are necessary. More studies 
are necessary to determine the best time point to restart TK 
inhibitor treatment for optimal outcome.18 Moreover, trials 
addressing this issue for solid tumor entities are missing so 
far. Apart from their imminent clinical relevance, these strat-
egies are also of biological interest as they address the ques-
tion, whether TKI may ultimately result in chronic disease 
control or may even have the potential to trigger cure.
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